Immunomodulatory Combinations of Antigen and Drug-Lipid Conjugate
US-2024374734-A1 · Nov 14, 2024 · US
17α-monoesters and 17α,21-diesters of cortexolone for use in the treatment of tumors
US11712443B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11712443-B2 |
| Application number | US-202117223776-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 6, 2021 |
| Priority date | Oct 8, 2014 |
| Publication date | Aug 1, 2023 |
| Grant date | Aug 1, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to certain cortexolone derivatives of formula (I)and the use of the same as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. The present invention also relates to pharmaceutical compositions comprising cortexolone derivatives of formula (I) as active ingredients and at least one physiologically acceptable excipient, and to the use of the pharmaceutical compositions as antitumor medicinal products.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a tumor disease in a subject in need thereof, comprising treating said subject with a therapeutically effective amount of a compound of formula: wherein the tumor disease is an adenocarcinoma, and wherein the adenocarcinoma is mammary carcinoma or gastrointestinal tract carcinoma. 2. The method of claim 1 , wherein the adenocarcinoma is mammary carcinoma. 3. The method of claim 2 , wherein the mammary carcinoma is triple negative breast cancer. 4. The method of claim 2 , wherein the subject is a relapsed or a non-responder to conventional therapy. 5. The method of claim 1 , wherein the adenocarcinoma is gastrointestinal tract carcinoma. 6. The method of claim 5 , wherein the gastrointestinal tract carcinoma is colon carcinoma.
Assignees
Inventors
Classifications
- A61K31/573Primary
substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone · CPC title
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
- C07J5/0053Primary
not substituted in position 16 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11712443B2 cover?
- The present invention relates to certain cortexolone derivatives of formula (I)and the use of the same as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. The present invention also relates to pharmaceutical compositions comprising …
- Who is the assignee on this patent?
- Cosmo Technologies Ltd, Cosmo Tech Limited
- What technology area does this patent fall under?
- Primary CPC classification A61K31/573. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).